Tirzepatide vs Retatrutide: What the 2026 Data Show

Two molecules from the same company, one receptor apart, and a gap of roughly eight percentage points on the scale. Tirzepatide is on pharmacy shelves with outcome data behind it; retatrutide has the larger weight-loss numbers and no approval anywhere in the world. This piece maps where the two compounds actually diverge: receptor pharmacology, trial magnitude, tolerability slope, and regulatory reality as of August 2026.

Key takeaways#

• Tirzepatide activates two receptors (GLP-1 and GIP). Retatrutide activates three, adding the glucagon receptor, which acts on energy expenditure rather than appetite.
• In SURMOUNT-1, tirzepatide 15 mg produced 20.9% mean weight reduction at 72 weeks. In TRIUMPH-1, retatrutide 12 mg produced 28.3% at 80 weeks, with 45.3% of participants losing 30% or more.
• The extra effect carries a tolerability cost: retatrutide discontinuation from adverse events ran 4.1%, 6.9% and 11.3% at 4 mg, 9 mg and 12 mg versus 4.9% on placebo.
• Tirzepatide has completed a cardiovascular outcomes trial (SURPASS-CVOT, 13,299 participants). Retatrutide has none finished, so its long-term risk picture is still open.
• No head-to-head trial has reported. TRIUMPH-5 is the registered direct comparison, and until it reads out every "vs" number here is cross-trial arithmetic.

The tirzepatide vs retatrutide difference is one receptor, and it is not a small one#

Tirzepatide is a single peptide that agonises the GLP-1 and GIP receptors. Retatrutide keeps both and adds the glucagon receptor (GCGR). Preclinical work on retatrutide (LY3437943) described a receptor balance intended to deliver glucose control, lipid changes and weight reduction through both decreased energy intake and increased energy expenditure .

That last clause is the whole story. GLP-1 and GIP agonism work mostly on the intake side: satiety, gastric emptying, glucose-dependent insulin secretion. Glucagon agonism works on the spending side, through hepatic lipid oxidation and thermogenesis. Activated alone it would raise blood glucose, which is why the incretin arms matter: they hold glycaemia while the glucagon arm draws down hepatic fat. The effects are not additive in a simple sense, they are complementary, hitting different halves of the energy-balance equation.

The hepatic signal is the cleanest evidence that the third receptor does something the first two do not. In a phase 2a substudy in participants with steatotic liver disease, mean relative liver-fat change at 24 weeks was -81.4% at 8 mg and -82.4% at 12 mg versus +0.3% on placebo, and normal liver fat (under 5%) was reached by 79% and 86% of those groups respectively, against 0% on placebo . Research suggests this exceeds what weight loss alone would predict at that timepoint.

On magnitude, retatrutide leads tirzepatide by roughly eight points, in separate trials#

The tirzepatide benchmark is SURMOUNT-1. It randomised 2,539 participants with obesity or overweight to once-weekly tirzepatide 5, 10 or 15 mg or placebo for 72 weeks, including a 20-week escalation period . At 15 mg with monthly brief lifestyle counselling, participants lost 20.9% of baseline weight at 72 weeks versus 3.1% on placebo . On the efficacy estimand, 39.7% of the 15 mg group reached at least 25% reduction against 0.3% on placebo, and fat mass fell about three times more than lean mass (33.9% versus 10.9%) .

The retatrutide benchmark moved twice in the past year. Phase 2 came first: in the 48-week NEJM trial of 338 adults, least-squares mean weight change was -8.7% at 1 mg, -17.1% at 4 mg, -22.8% at 8 mg and -24.2% at 12 mg versus -2.1% on placebo . Then phase 3. In TRIUMPH-1, by 80 weeks average losses ran 19.0% at 4 mg, 25.9% at 9 mg and 28.3% at 12 mg, against 2.2% on placebo . 45.3% of the 12 mg group reached 30% or more, a threshold long associated with bariatric surgery, and participants with baseline BMI 35 or above who entered a study extension reached an average of 30.3% at 104 weeks . 65.3% of the 12 mg group dropped below the obesity BMI threshold by week 80 .

Two caveats keep this honest. First, the trials differ in duration (72 versus 80 weeks), population, escalation schedule and estimand, so the gap is an estimate, not a measured difference. Second, retatrutide's curve had not flattened when tirzepatide's had. That is visible in the trajectory, not the endpoint.

Tolerability, not efficacy, is where tirzepatide vs retatrutide gets interesting#

Both compounds are gastrointestinal in their side-effect signature. The difference is the slope. In phase 2, the most common retatrutide adverse events were gastrointestinal, dose-related, mostly mild to moderate, and partially mitigated by a lower 2 mg starting dose instead of 4 mg; dose-dependent heart-rate increases peaked at 24 weeks and declined thereafter .

Phase 3 quantified the dropout curve. Discontinuations rose with dose: 4.1%, 6.9% and 11.3% at 4, 9 and 12 mg, against 4.9% on placebo , and vomiting was reported by 10.6%, 22.8% and 25.3% of retatrutide participants versus 4.8% on placebo, with upper respiratory infections, urinary tract infections and mild to moderate dysesthesia also observed . The dysesthesia signal has no equivalent in the tirzepatide label and deserves watching.

The practical read is that dose choice matters more than compound choice. The 4 mg arm, reached with a single escalation step, still delivered 19.0% at 80 weeks , which is within reach of tirzepatide's 15 mg result at a discontinuation rate below placebo. Studies have shown the same pattern across the incretin class: the top dose buys percentage points and pays in titration attrition.

For tirzepatide, the comparative tolerability data are more mature. In SURPASS-CVOT, gastrointestinal adverse events occurred in 42.5% of tirzepatide-treated patients versus 35.9% on dulaglutide, with other adverse events similar .

Tirzepatide has outcome data; retatrutide has weight data#

This is the asymmetry most comparisons skip. Weight loss is a surrogate. Events are the endpoint that changes guidelines.

Tirzepatide has cleared that bar. In the double-blind SURPASS-CVOT noninferiority trial published in NEJM in December 2025, tirzepatide was noninferior to dulaglutide for the composite of cardiovascular death, myocardial infarction or stroke in patients with type 2 diabetes and atherosclerotic disease, with 6,586 assigned to tirzepatide and 6,579 to dulaglutide . Reported alongside were an approximately 8% relative reduction in three-point MACE and a 16% reduction in all-cause mortality versus dulaglutide, with larger reductions in blood pressure and lipids . The full report is available via NEJM. A post hoc cardiorenal analysis found the composite endpoint in 23.7% of tirzepatide patients versus 27.4% on dulaglutide (HR 0.84, 95% CI 0.79-0.90) .

Retatrutide's surrogate markers look strong. A meta-analysis of randomised trials found systolic blood pressure down 6.79 mmHg, diastolic down 2.46 mmHg, total cholesterol down 21.88 mg/dL, LDL-C down 13.10 mg/dL and triglycerides down 40.90 mg/dL . In phase 2, 41% of the combined 8 mg group and 30% of the 12 mg group discontinued at least one antihypertensive during 48 weeks . That is preliminary evidence of cardiometabolic benefit, not proof of event reduction. TRIUMPH-Outcomes is the long-term cardiovascular and renal outcomes trial, with a primary composite broader than classic three-point MACE, including heart-failure events alongside cardiovascular death, non-fatal MI and non-fatal stroke .

Indication breadth follows the same pattern. Tirzepatide already carries approvals beyond weight: type 2 diabetes in May 2022, chronic weight management in November 2023, and moderate-to-severe obstructive sleep apnea in adults with obesity in December 2024 , the latter documented in the FDA announcement. Retatrutide's phase 3 programme is chasing similar ground: TRIUMPH-4 reported 23.7% mean weight loss at 68 weeks in participants with obesity and knee osteoarthritis, alongside reductions in knee pain .

Availability, not pharmacology, decides the tirzepatide vs retatrutide question in 2026#

Tirzepatide is dispensable today. In Norway it is marketed as Mounjaro since November 2024, approved for both weight reduction and type 2 diabetes, with around 3,700 users by the end of 2024 according to FHI. Reimbursement is the constraint rather than access: as of April 2026 there is no pre-approved blue-prescription reimbursement for weight indications in Norway .

Retatrutide is not purchasable as a prescribed product anywhere. It remains investigational under Eli Lilly's phase 3 programme, with no FDA approval, no EMA approval and no prescription pathway . Research-grade retatrutide circulates through specialised suppliers under research-use-only framing, which carries no identity, purity or sterility assurance comparable to a licensed product. Klarovel does not stock or sell peptides; partner suppliers fulfil, and the protocol layer is what Klarovel curates. Our disclosures page sets out that boundary.

The data package is now largely assembled. Following positive TRIUMPH-2 and TRIUMPH-3 readouts in July 2026, all four core registrational trials have reported, with a Biologics License Application expected in Q1 2027 . TRIUMPH-2 covers obesity with type 2 diabetes and TRIUMPH-3 covers obesity with established cardiovascular disease .

The comparison that will actually settle this has not reported#

Everything above is indirect. TRIUMPH-5 is the phase 3 head-to-head efficacy trial comparing retatrutide with tirzepatide in adults with obesity, with percent change in body weight as the primary outcome, and it is the first direct randomised comparison of the two molecules . Cross-trial gaps of eight percentage points have shrunk before when tested directly, and they have also held. The SURMOUNT-5 precedent is instructive: in a 751-participant head-to-head, least-squares mean change at week 72 was -20.2% for tirzepatide versus -13.7% for semaglutide , roughly consistent with the cross-trial estimate at the time.

Until TRIUMPH-5 reads out, the defensible statement is narrow: retatrutide's phase 3 magnitude exceeds tirzepatide's phase 3 magnitude in separate trials, at a higher titration-attrition cost, without outcome data. If you are building a tracking protocol around either compound, our peptide calculator handles the escalation arithmetic, and how it works explains where protocol structure ends and prescriber judgement begins. For the previous step in this receptor sequence, see the tirzepatide versus semaglutide comparison.

The honest verdict on tirzepatide vs retatrutide#

Retatrutide is the more interesting molecule and tirzepatide is the more usable one. That is not a hedge, it is the state of the evidence in August 2026: one compound with 28.3% at 80 weeks and no approval, one with 20.9% at 72 weeks, a completed outcomes trial across 13,299 patients and three approved indications. Anyone framing this as a settled hierarchy is skipping the trial that will decide it.

Klarovel builds the protocol layer around compounds like these: escalation logic, tracking cadence, and the documentation that makes a prescriber conversation productive rather than adversarial. Create an account to structure your own tracking before the next TRIUMPH readout changes the arithmetic again.